Baseline Characteristics, Including Hospitalizations, of Asthma Patients Treated with Dupilumab in the Real World: The Rapid Registry
Author(s)
Lugogo NL1, Soler X2, Peters AT3, Cote A4, Hilberg O5, Wang Z2, Xia C2, Zhang Y2, Gómez LDP6, Jacob-Nara JA7, Radwan A2, Rowe PJ7, Deniz Y2
1University of Michigan, Ann Arbor, MI, USA, 2Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA, 3Northwestern University Feinberg School of Medicine, Chicago, IL, USA, 4Quebec Heart and Lung Institute – Laval University, Quebec, QC, Canada, 5Lillebaelt Hospital, Vejle, Denmark, 6Sanofi, Madrid, Spain, 7Sanofi, Bridgewater, NJ, USA
Presentation Documents
OBJECTIVES:
Dupilumab is a fully human monoclonal antibody that blocks interleukin (IL)- 4/13, key and central drivers of type 2 inflammation. This analysis was aimed at the characterization of patients with asthma initiating therapy with dupilumab and enrolled in the RAPID (NCT04287621) registry study.METHODS:
RAPID is a global, prospective registry enrolling patients aged ≥12 years who initiated dupilumab treatment for a primary indication of asthma.RESULTS:
Between 03/2020 and 10/2021, 205 patients were enrolled, with the following characteristics at baseline: age (years, mean [SD]): 50.1 (17.4); body mass index (kg/m2, mean [SD]): 30.67 (7.96); female: 65.4%; 74.1% were White (including Hispanic or Latino), 13.2% Black or African American. 86.8% of patients had moderate-to-severe asthma according to the Global Initiative for Asthma severity score (3-5) and 24.4% of patients were current/former smokers. The 78 participants reporting asthma exacerbations had a mean (SD) of 4.4 (6.44) exacerbations in the year before the screening. Number of hospitalizations in the previous year (n=205, mean [SD]): 0.2 (0.81), with 9.3% patients hospitalized and 18.5% visiting the emergency department; 6-item Asthma Control Questionnaire score (n=193, mean [SD]): 2.4 (1.18); Asthma Quality of Life Questionnaire (n= 192, mean [SD]): 4.1 (1.31); pre-bronchodilator forced expiratory volume in 1 second (FEV1) (L, n=89, mean [SD]): 2.29 (1.14); post-bronchodilator FEV1 (L, n=44, mean [SD]): 2.48 (1.16); forced vital capacity (L, n=89, mean [SD]): 3.09 (1.08); peak expiratory flow (L/min, n=68, mean [SD]): 356.88 (169.83); fractional exhaled nitric oxide (ppb, n=61, mean [SD]): 42.2 (34.83); eosinophil count (cells/μL, n=64, mean [SD]): 492.7 (443.46), ranging between 0.0 – 2142.0 cells/μL.CONCLUSIONS:
At the time of enrollment, the majority of patients were female, with a high disease burden as observed through exacerbation history, impaired lung function, elevated mean levels of type 2 biomarkers and poor asthma control and quality of life.Conference/Value in Health Info
2023-05, ISPOR 2023, Boston, MA, USA
Value in Health, Volume 26, Issue 6, S2 (June 2023)
Code
CO170
Topic
Clinical Outcomes
Topic Subcategory
Clinician Reported Outcomes
Disease
Drugs